Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health


Personal tools

You are here: Home / Biomarkers / Wu 6-marker phage peptide panel for Lung Cancer

Wu 6-marker phage peptide panel for Lung Cancer



QA State: Curated
Short Name:
HGNC Name:

The six-phage peptide detector stands out as a promising diagnostic biomarker for NSCLC. The peptide panel could be used to diagnose non-small cell lung cancer and to differentiate between non-small cell lung cancer and chronic obstructive pulmonary diseases. One of the six phage peptides shows 100% homology to olfactomedin 1. (Clin Cancer Res. 2010 Jul 15;16(14):3760-8. doi: 10.1158/1078-0432.CCR-10-0193) The other five peptides were homologous to proteins in a blastp search, but the homology was not high enough to positively identify the peptides.

Panel Details


There are no datasets associated with this biomarker.


The following organs have data associated with this biomarker…



Phase: Two
QA State: Curated


The six-phage peptide detector could be used to diagnose NSCLC at early stage and discriminate NSCLC and chronic obstructive pulmonary diseases. Chemotherapy significantly reduced the seroreactivity of the six-phage peptide clones. The six-phage peptide detector can be used as a novel method for noninvasive diagnosis and screening of NSCLC in high-risk populations. However, it is unlikely to be used as biomarkers for indicating the relapse of NSCLC after chemotherapy. (Clin Cancer Res. 2010 Jul 15;16(14):3760-8. doi: 10.1158/1078-0432.CCR-10-0193)


This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at if you should have access to this biomarker.


No associated resources found.

2015 Steering Committee Meeting

The next EDRN Steering Committee Meeting will take place March 31st through April 2nd, 2015, in Atlanta, Georgia.

Announcement 12/02/2014

New Round of EDRN FOAs

The RFAs for EDRN have been released:
- Biomarker Developmental Laboratories (U01),
- Clinical Validation Centers (U01),
- Biomarker Reference Laboratories (U24),
- Data Management and Coordinating Center (U24).

EDRN Renewal flyer NOTE-New receipt deadline for applications submitted for all EDRN FOAs is January 20, 2015, by 5:00 PM local time of applicant organization.

There will be a Pre-Application webinar to discuss each of the four individual EDRN FOAs on Tuesday, December 2nd, 2014, from 1pm-5pm (Eastern). Potential applicants interested in participating in the webinar should send a message to Dr. Sharmistha Ghosh ( no later than 5:00 p.m. (EST) November 21, 2014. Please mention the FOA of interest in the subject line.

Announcement 10/07/2014

EDRN Patient Advocates will host an EDRN Advocacy Educational Webinar, Biomarkers for Prostate Cancer Detection and Monitoring, on Monday, January 12th, 2015, at 1 p.m. EDT / 10 a.m. PDT. Registration is not required for this. Please click for more information.